Novel therapeutic targets in depression: Minocycline as a candidate treatment

Página do item simplificado
dc.contributor.authorSoczynska, Joanna K.
dc.contributor.authorMansur, Rodrigo B. [UNIFESP]
dc.contributor.authorBrietzke, Elisa [UNIFESP]
dc.contributor.authorSwardfager, Walter
dc.contributor.authorKennedy, Sidney H.
dc.contributor.authorWoldeyohannes, Hanna O.
dc.contributor.authorPowell, Alissa M.
dc.contributor.authorManierka, Marena S.
dc.contributor.authorMcIntyre, Roger S.
dc.contributor.institutionUniv Toronto
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionSunnybrook Hlth Sci Ctr
dc.date.accessioned2016-01-24T14:28:05Z
dc.date.available2016-01-24T14:28:05Z
dc.date.issued2012-12-01
dc.description.abstractMood disorders are marked by high rates of non-recovery, recurrence, and chronicity, which are insufficiently addressed by current therapies. Several patho-etiological models have been proposed that are not mutually exclusive and include but are not limited to the monoamine, inflammatory, neurotrophic, gliotrophic, excitatory, and oxidative stress systems. A derivative of these observations is that treatment(s) which target one or more of these mechanistic steps may be capable of mitigating, or preventing, disparate psychopathological features. Minocycline is an agent with pleiotropic properties that targets multiple proteins and cellular processes implicated in the patho-etiology of mood disorders. Moreover, preclinical and preliminary clinical evidence suggests that minocycline possesses antidepressant properties. Herein, we provide the rationale for conducting a randomized, controlled trial to test the antidepressant properties of minocycline. (C) 2012 Elsevier B.V. All rights reserved.en
dc.description.affiliationUniv Toronto, Mood Disorders Psychopharmacol Unit, Univ Hlth Network, Dept Psychiat, Toronto, ON M5T 2S8, Canada
dc.description.affiliationUniv Toronto, Inst Med Sci, Toronto, ON M5T 2S8, Canada
dc.description.affiliationUniversidade Federal de São Paulo, Dept Psychiat, Program Recognit & Intervent Individuals Risk Men, São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Dept Psychiat, Interdisciplinary Lab Clin Neurosci LINC, São Paulo, Brazil
dc.description.affiliationUniv Toronto, Dept Pharmacol, Toronto, ON M5T 2S8, Canada
dc.description.affiliationUniv Toronto, Dept Toxicol, Toronto, ON M5T 2S8, Canada
dc.description.affiliationSunnybrook Hlth Sci Ctr, Neuropsychopharrnacol Res Grp, Toronto, ON M4N 3M5, Canada
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Psychiat, Program Recognit & Intervent Individuals Risk Men, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Psychiat, Interdisciplinary Lab Clin Neurosci LINC, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipEli Lilly
dc.description.sponsorshipJanssen-Ortho
dc.description.sponsorshipAstra Zeneca
dc.description.sponsorshipBristol-Meyers Squibb
dc.description.sponsorshipClera, Inc.
dc.description.sponsorshipGlaxo Smith Kline
dc.description.sponsorshipLundbeck
dc.description.sponsorshipPfizer
dc.description.sponsorshipServier
dc.description.sponsorshipSt. Jude Medical
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipToronto Rehabilitation Institute
dc.description.sponsorshipHeart and Stroke Foundation Centre for Stroke Recovery
dc.description.sponsorshipStanley Medical Research Institute
dc.description.sponsorshipNational Alliance for Research on Schizophrenia and Depression (NARSAD)
dc.description.sponsorshipNational Institutes of Mental Health
dc.description.sponsorshipShire
dc.description.sponsorshipAstra-Zeneca
dc.description.sponsorshipForest
dc.description.sponsorshipSepracor
dc.format.extent302-317
dc.identifierhttp://dx.doi.org/10.1016/j.bbr.2012.07.026
dc.identifier.citationBehavioural Brain Research. Amsterdam: Elsevier B.V., v. 235, n. 2, p. 302-317, 2012.
dc.identifier.doi10.1016/j.bbr.2012.07.026
dc.identifier.issn0166-4328
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/35555
dc.identifier.wosWOS:000309801400026
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofBehavioural Brain Research
dc.rightsAcesso restrito
dc.rights.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.subjectBipolar disorderen
dc.subjectMajor depressionen
dc.subjectInflammationen
dc.subjectNeuroplasticityen
dc.subjectGlutamateen
dc.subjectOxidative stressen
dc.subjectMinocyclineen
dc.titleNovel therapeutic targets in depression: Minocycline as a candidate treatmenten
dc.typeResenha
Arquivos
Coleções
EPM - Outras produções